0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Long-Term Amphotericin B Therapy for Disseminated Histoplasmosis in Patients with the Acquired Immunodeficiency Syndrome (AIDS)

David S. McKinsey, MD; Mala R. Gupta, MD; Sharon A. Riddler, MD; Michael R. Driks, MD; David L. Smith, MD; and Paul J. Kurtin, MD
[+] Article and Author Information

This paper was presented in part at the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, 25 October 1988, Los Angeles, California.

Requests for Reprints: David S. McKinsey, MD, Department of Epidemiology and Infectious Disease, Research Medical Center, 2316 East Meyer Boulevard, Kansas City, MO 64132.

Current Author Addresses: Drs. McKinsey and Smith: Research Medical Center, 2316 East Meyer Boulevard, Kansas City, MO 64132.

Dr. Gupta: Trinity Lutheran Hospital, 3030 Baltimore, Kansas City, MO 64108.

Dr. Riddler: Truman Medical Center, 2301 Holmes, Kansas City, MO 64108.

Dr. Driks: Baptist Medical Center, 6601 Rockhill Road, Kansas City, MO 64131.

Dr. Kurtin: Mayo Clinic, Rochester, MN 55905.


©1989 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1989;111(8):655-659. doi:10.7326/0003-4819-111-8-655
Text Size: A A A

Study Objective: To assess the efficacy and toxicity of long-term maintenance amphotericin B therapy in preventing relapses after treatment in patients with the acquired immunodeficiency syndrome (AIDS) and disseminated histoplasmosis.

Design: Open, nonrandomized pilot study.

Setting: Three private, university-affiliated community hospitals.

Patients: We studied 22 consecutive patients with disseminated histoplasmosis and human immunodeficiency virus (HIV) infection. Sixteen patients completed the study, 5 patients died before completing the initial intensive phase of treatment, and 1 patient received a different treatment regimen.

Interventions: Seven patients were treated with an initial intensive course of 1000 mg of amphotericin B, followed by weekly infusions of 50 to 80 mg until a cumulative dose of 2000 mg was attained; biweekly infusions of 50 to 80 mg were then continued indefinitely. Nine patients received an initial amphotericin B course of 2000 mg followed by weekly infusions of 80 mg.

Measurements and Main Results: Of the 7 patients in the 1000-mg intensive regimen group, 6 patients have survived without clinical or laboratory evidence of a histoplasmosis relapse, and 1 died of unrelated causes. Of the 9 patients in the 2000-mg intensive regimen group, 7 patients have survived, 1 patient died of a histoplasmosis relapse, and 1 patient died of other causes. Thus, 13 of 14 patients (93%) who did not die of other causes remained relapse-free. The median follow-up period was 14 months (range, 2 to 23 months). No apparent differences in outcome were observed between patients treated with weekly maintenance regimens and those treated with biweekly maintenance regimens. Sixty-three percent of patients developed intravascular device-related complications.

Conclusions: Long-term, intermittent maintenance amphotericin B therapy in HIV-infected patients with disseminated histoplasmosis is well tolerated and is highly effective in suppressing relapses after treatment.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)